A Randomized Placebo-Controlled Trial of the Efficacy of Preventive Dosage of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism in Patients Undergoing Coronary Artery Bypass Graft Surgery (CABG).

Trial Profile

A Randomized Placebo-Controlled Trial of the Efficacy of Preventive Dosage of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism in Patients Undergoing Coronary Artery Bypass Graft Surgery (CABG).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2015

At a glance

  • Drugs Fondaparinux sodium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Dec 2015 As per an article published in the American Heart Journal, this trial has been terminated early because of the relocation of the principal investigator to a new institution.
    • 29 Dec 2015 Status changed from active, no longer recruiting to discontinued, as per an article published in the American Heart Journal
    • 29 Dec 2015 Results published in the American Heart Journal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top